Literature DB >> 36094314

The Epstein-Barr Virus Enhancer Interaction Landscapes in Virus-Associated Cancer Cell Lines.

Weiyue Ding1, Chong Wang1, Yohei Narita1, Hongbo Wang1, Merrin Man Long Leong1, Alvin Huang1, Yifei Liao1, Xuefeng Liu2, Yusuke Okuno3, Hiroshi Kimura4, Benjamin Gewurz1, Mingxian Teng5, Shuilin Jin6, Yoshitaka Sato4, Bo Zhao1.   

Abstract

Epstein-Barr virus (EBV) persists in human cells as episomes. EBV episomes are chromatinized and their 3D conformation varies greatly in cells expressing different latency genes. We used HiChIP, an assay which combines genome-wide chromatin conformation capture followed by deep sequencing (Hi-C) and chromatin immunoprecipitation (ChIP), to interrogate the EBV episome 3D conformation in different cancer cell lines. In an EBV-transformed lymphoblastoid cell line (LCL) GM12878 expressing type III EBV latency genes, abundant genomic interactions were identified by H3K27ac HiChIP. A strong enhancer was located near the BILF2 gene and looped to multiple genes around BALFs loci. Perturbation of the BILF2 enhancer by CRISPR interference (CRISPRi) and CRISPR activation (CRISPRa) altered the expression of BILF2 enhancer-linked genes, including BARF0 and BALF2, suggesting that this enhancer regulates the expression of linked genes. H3K27ac ChIP followed by deep sequencing (ChIP-seq) identified several strong EBV enhancers in T/NK (natural killer) lymphoma cells that express type II EBV latency genes. Extensive intragenomic interactions were also found which linked enhancers to target genes. A strong enhancer at BILF2 also looped to the BALF loci. CRISPRi also validated the functional connection between BILF2 enhancer and BARF1 gene. In contrast, H3K27ac HiChIP found significantly fewer intragenomic interactions in type I EBV latency gene-expressing primary effusion lymphoma (PEL) cell lines. These data provided new insight into the regulation of EBV latency gene expression in different EBV-associated tumors. IMPORTANCE EBV is the first human DNA tumor virus identified, discovered over 50 years ago. EBV causes ~200,000 cases of various cancers each year. EBV-encoded oncogenes, noncoding RNAs, and microRNAs (miRNAs) can promote cell growth and survival and suppress senescence. Regulation of EBV gene expression is very complex. The viral C promoter regulates the expression of all EBV nuclear antigens (EBNAs), some of which are very far away from the C promoter. Another way by which the virus activates remote gene expression is through DNA looping. In this study, we describe the viral genome looping patterns in various EBV-associated cancer cell lines and identify important EBV enhancers in these cells. This study also identified novel opportunities to perturb and eventually control EBV gene expression in these cancer cells.

Entities:  

Keywords:  3D genome organization; Epstein-Barr virus; episome; latency

Mesh:

Substances:

Year:  2022        PMID: 36094314      PMCID: PMC9517713          DOI: 10.1128/jvi.00739-22

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   6.549


  44 in total

1.  VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA.

Authors:  M A EPSTEIN; B G ACHONG; Y M BARR
Journal:  Lancet       Date:  1964-03-28       Impact factor: 79.321

2.  The NORAD lncRNA assembles a topoisomerase complex critical for genome stability.

Authors:  Mathias Munschauer; Celina T Nguyen; Klara Sirokman; Christina R Hartigan; Larson Hogstrom; Jesse M Engreitz; Jacob C Ulirsch; Charles P Fulco; Vidya Subramanian; Jenny Chen; Monica Schenone; Mitchell Guttman; Steven A Carr; Eric S Lander
Journal:  Nature       Date:  2018-08-27       Impact factor: 49.962

3.  Characterization of Epstein-Barr virus (EBV)-infected natural killer (NK) cell proliferation in patients with severe mosquito allergy; establishment of an IL-2-dependent NK-like cell line.

Authors:  I Tsuge; T Morishima; M Morita; H Kimura; K Kuzushima; H Matsuoka
Journal:  Clin Exp Immunol       Date:  1999-03       Impact factor: 4.330

4.  Preferential expansion of Vgamma9-JgammaP/Vdelta2-Jdelta3 gammadelta T cells in nasal T-cell lymphoma and chronic active Epstein-Barr virus infection.

Authors:  Michiko K Oyoshi; Hiroshi Nagata; Nobuhiro Kimura; Yu Zhang; Ayako Demachi; Toshiro Hara; Hirokazu Kanegane; Yoshinobu Matsuo; Tomohiro Yamaguchi; Tomohiro Morio; Atsuyoshi Hirano; Norio Shimizu; Kohtaro Yamamoto
Journal:  Am J Pathol       Date:  2003-05       Impact factor: 4.307

5.  The DNA segregation mechanism of Epstein-Barr virus nuclear antigen 1.

Authors:  H Wu; D F Ceccarelli; L Frappier
Journal:  EMBO Rep       Date:  2000-08       Impact factor: 8.807

6.  An Epstein-Barr Virus MicroRNA Blocks Interleukin-1 (IL-1) Signaling by Targeting IL-1 Receptor 1.

Authors:  Camille M Skinner; Nikita S Ivanov; Sarah A Barr; Yan Chen; Rebecca L Skalsky
Journal:  J Virol       Date:  2017-10-13       Impact factor: 5.103

7.  Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation.

Authors:  S Harada; E Kieff
Journal:  J Virol       Date:  1997-09       Impact factor: 5.103

Review 8.  Control of Viral Latency by Episome Maintenance Proteins.

Authors:  Alessandra De Leo; Abram Calderon; Paul M Lieberman
Journal:  Trends Microbiol       Date:  2019-10-14       Impact factor: 17.079

9.  Epstein-Barr virus nuclear antigen EBNA-LP is essential for transforming naïve B cells, and facilitates recruitment of transcription factors to the viral genome.

Authors:  Agnieszka Szymula; Richard D Palermo; Amr Bayoumy; Ian J Groves; Mohammed Ba Abdullah; Beth Holder; Robert E White
Journal:  PLoS Pathog       Date:  2018-02-20       Impact factor: 6.823

10.  Epstein-Barr virus ncRNA from a nasopharyngeal carcinoma induces an inflammatory response that promotes virus production.

Authors:  Zhe Li; Ming-Han Tsai; Anatoliy Shumilov; Francesco Baccianti; Sai Wah Tsao; Remy Poirey; Henri-Jacques Delecluse
Journal:  Nat Microbiol       Date:  2019-09-09       Impact factor: 17.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.